Episodes
Thursday Sep 29, 2016
Eleven Things Every Clinician Should Know About the “Egregious Eleven”
Thursday Sep 29, 2016
Thursday Sep 29, 2016
A recent paper published in Diabetes Care proposing a new classification system for diabetes challenges our existing paradigm and has significant implications for our treatment approach for diabetes.
Thursday Sep 15, 2016
HIP-HIP-HOPE-3! Expanded role for statin therapy for primary prevention
Thursday Sep 15, 2016
Thursday Sep 15, 2016
The HOPE-3 trial sought to determine if blood pressure (BP) and cholesterol-lowering therapies are effective and safe as primary prevention strategies in intermediate risk patients. The American College of Cardiology and American Heart Association (ACC/AHA) guidelines support a risk-based approach to statin use but in intermediate risk patients the tradeoffs between benefit and risk were deemed “less clear.” Do the results of HOPE-3 trial provide enough evidence to support routinely treating intermediate risk patients?
Friday Sep 02, 2016
Liraglutide: the new LEADER for second line therapy in diabetes management?
Friday Sep 02, 2016
Friday Sep 02, 2016
According to the current (2016) ADA guidelines, no agent is “the preferred” second line therapy after metformin monotherapy — instead the benefits, risks, cost, and convenience of each option should be considered and treatment should be individualized. The liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER) trial, which assessed the long-term cardiovascular effects of liraglutide, a GLP-1 receptor agonist, comes at an interesting time shortly after the publication of the empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) trial. Both studies found a cardiovascular benefit. How, then, will the results of these trials affect the algorithm for type 2 diabetes management and more importantly, clinical practice?